forget about houses and listen to what Avacta are developing and working on today, just like they were yesterday! Nothing has changed we are still targeting tech transfer of LFT and professional CE marking in Q4 and BAMS validation (all be it hindered by CONDOR) in Q4
Personally I think this move will bode very well for Dr Al. There two scenarios: 1. He gets a massive fine for insider trading selling before it all goes horribly wrong
2. He gets praised for selling his shares before the share price rockets to £20 and he would have been lambasted for buying a new house off the back of COVID.
Lets not forget why we are here and the basis of all Avacta's tests are Affimers. Which have been proved to be highly sensitive in detection of the S1 spike protein of SARS-CoV-2 and show Exquisite specificity.
They are already commercially available for research tools in the following tests:
ELISA BAMS
The same Affimers are also utilised for:
-Lateral flow devices - currently being tech transferred to BBI and manufacturing being scaled up to meet global demand
-Collaboration with Integumen plc (AIM: SKIN) ("Integumen") to evaluate recently generated Affimer reagents that bind the SARS-CoV-2 spike protein for the detection of the corona virus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks
-Daewoong are developing stem cell treatments incorporating Avacta's neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.
We were told validation of both LFT and BAMS is targeted for Q4 and its still early Q4